Drug intelligence / Profile preview

DA5221-T2 + DA5221-B1 + DA5221-B2

Development stage: Unknown
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA5221-T2 + DA5221-B1 + DA5221-B2 is an investigational **oral combination therapy** for **type 2 diabetes mellitus**, currently in late-stage clinical development. The regimen combines **DA5221-T2**, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with **DA5221-B1** and **DA5221-B2**, with the latter identified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination targets glycemic control in patients inadequately managed with DPP-4 inhibitor dual therapy. The development is led by Dong-A ST, and clinical trials focus on efficacy (HbA1c reduction) and safety in adults with type 2 diabetes[1][2][3][5][7].

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on DA5221-T2 + DA5221-B1 + DA5221-B2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA5221-T2 + DA5221-B1 + DA5221-B2.

Explore the full profile